Consequently, the company says the sheep sector is going to have to take a more proactive approach to parasite control if it is to achieve the best possible environmental standards.
The research by SRUC and the Moredun Research Institute showed parasite infections in lambs can lead to a 33% increase in methane output1 and that parasitism is one of the top three livestock diseases which increase greenhouse gas (GHG) emissions2 and is cost-effective to manage.
Eurion Thomas, European operations manager at Techion, says that despite current emissions from sheep being over-exaggerated, the sector will need to act if the NFU’s aspiration for net zero emissions from agriculture by 2040, is to be achieved.
Eurion said: "While targets to further reduce GHG emissions may appear to be burdensome, there are some simple steps farmers can take that’ll help minimise emissions while also improving business profitability. This includes incorporating regular faecal egg counts (FEC) into routine flock management to increase the accuracy of worm control.
"Worms reduce performance, in particular feed conversion ratio (FCR) meaning animals take longer to finish at lower weights. In addition, the research shows animals with worms release more methane per day due to the upset they cause to the digestive system.
"Better parasite control can therefore reduce number of days to finishing, improving production efficiency and lowering methane emissions per unit of meat produced. The number of days to slaughter and FCR are also correlated to profit margins, providing an opportunity to improve the bottom line."
Eurion says one of the reasons endemic diseases such as worm burdens are so detrimental to production efficiency and emissions is because often the disease has significantly impacted animal performance before it has been identified. Regular faecal egg counts (FEC) and an accurate treatment programme are therefore crucial.
Eurion said: "FECPAKG2 is the latest in image-based, internet-connected, FEC technology and means testing can be carried out virtually anywhere by anyone, including on-farm by the farmer.
"Because digital images of parasite eggs are produced, analysed and stored online, FECPAKG2 provides rapid results while offering greater quality control and auditability. This is encouraging more frequent testing and better decision making at farm level."
A collaborative research project between Sainsbury’s and Techion3 showed accurate treatment of the right animals, with the right wormer, at the right time, improved daily liveweight gains (DLWG) while reducing wormer use in sheep by up to 50%.
Eurion said: "Addressing the environmental impact of red meat production is arguably one of the biggest challenges the sector faces and introducing FEC is one simple way farmers can proactively work towards this, while improving business profitability."
References
Merial Animal Health has launched Allevinix, a flunixin-based non-steroidal anti-inflammatory (NSAID) pain killer for cattle, pigs and horses.
Victoria Hudson, Product Manager for Merial Animal Health said: "We have positioned Allevinix as the flexible flunixin that meets your needs, because it offers flexibility in every area.
"It is the only flunixin licensed for both intramuscular and intravenous administration in cattle and we know that this will be very welcome for many vets and farmers. It can be used across cattle, pigs and horses, and it is the first injectable NSAID to come in a durable, non-breakable bottle."
Merial says Allevinix is fast-acting against inflammation, pain and fever, reaching peak plasma levels approximately 30 minutes after injection. It is available in 100ml and 250ml PET bottles and joins Ketofen as part of a range of NSAIDs available from Merial. It can also be used in conjunction with Merial's antimicrobial treatment for calf pneumonia - Zactran.
Victoria added: "We believe that vets will find this is a useful and innovative addition to the range of options that they have in terms of NSAIDs. Allevinix has a number of advantages over other flunixin products currently on the market."
Xperior Farm Health, one of the bidders for the government contracts to provide TB testing, has announced that it mounted a legal challenge to the procurement process, but has now withdrawn that challenge in the face of the 'aggressive' timeframe in which Defra demanded that it submit its case.
Xperior says it was made aware last month that all five Delivery Partner contracts would be awarded to members of the same veterinary group (XL Vets), which it felt would both compromise competition and make Defra overly reliant on one service provider.
In addition, Xperior said it believed the successful bids were unfeasibly low, which presents a potentially devastating threat to the viability of many rural vet practices and a seriously reduced quality of TB testing service to farmers.
Xperior says it initially notified a formal query to the Animal and Plant Health Agency (APHA - the executive agency of Defra responsible for awarding the contracts) during the pre-announcement consultation period, and believes other bidders may have done likewise. The query was dismissed, as a result of which the company issued legal proceedings.
Xperior's Veterinary Director, Phil Elkins said: "We are concerned that proposed payment rates for TB testing are considerably lower than those proposed by other bidders, and at a level which questions the viability of practices continuing to provide TB testing services to their clients.
"The consequence would be either unfairly low payment rates for official veterinarians (OVs) who conduct TB testing, or an influx of inexperienced vets, potentially from other countries, into low paid positions. The loss of TB testing income would also challenge the viability of some rural veterinary businesses and the relationships held with their clients.
"Either way, this is contrary to a key tenet in the pre-tender documentation that Delivery Partners are expected to maintain a flow of TB testing work and revenue to contribute to the capability of the veterinary profession in rural areas to support food security and the rural economy."
Meanwhile, an APHA spokesperson said they were limited in how much they could say before the formal announcement of the award, except that: “APHA is confident in the robustness of the procurement process and that the selected bidders are the best candidates to deliver this vital service in the most effective way.”
VetSurgeon.org understands that now the legal challenge has been dropped, an official announcement of the winner will likely be made within days. However, it also seems likely that the payment rates for OVs will remain confidential even after the announcement of the award, so it may be some time before the prospects for OVs become clear.
Mr Chalkley faced three charges against him. The first was that he failed to identify some or all of the animals tested with Intradermal Comparative Tuberculin (ICT) tests at the farm.
The second charge was that Mr Chalkley had certified that he had carried out ICT tests on 279 animals at the farm and recorded the results on the accompanying paperwork but had, in fact, not adequately identified some or all of the 279 animals and had fabricated the skin thickness measurements recorded for some of them.
In addition, the charge alleged that Mr Chalkley’s conduct was dishonest, misleading and risked undermining government testing procedures designed to promote public health.
The third charge was that between June 2011 and September 2018, Mr Chalkley received payment of approximately £20,000 for ICT tests when, as a result of his conduct in relation to ICT tests at the farm, he was not entitled to such payment.
At the outset of the hearing Mr Chalkley admitted the first charge, that he had not adequately identified some of the animals.
On the third day of the hearing, during his evidence to the Committee, he admitted that his certification of the ICT testing was therefore misleading.
He denied the rest of the charges including that his conduct had been dishonest and that it had risked undermining government testing procedures designed to promote public health.
In considering the charges against Mr Chalkley, the Committee heard that discrepancies regarding the tests that were carried out on the farm in March 2018 were originally raised by the Animal and Plant Health Agency (APHA), on whose behalf Mr Chalkley carried out ICT testing in his capacity as an Official Veterinarian.
When Mr Chalkley gave evidence during the hearing, he explained that he had taken over TB testing for the farm in 2008 and that working conditions on the farm had been difficult throughout the whole period 2008 to 2018. He stated that due to the harsh weather conditions of early 2018, TB testing was difficult, and that the farmer needed to complete the test by March 2018 to avoid a financial penalty.
Mr Chalkley explained that one of the reasons for there being limited time available for him to carry out the test within the time required by the farmer was that he was due to provide veterinary cover at the Cheltenham races the following week and he was unable to find anyone else to cover the tests. Mr Chalkley also explained that during the tests on 5 and 8 March there had been limited farmhands available to assist in processing the cattle through the tests.
In the course of being asked questions by counsel for the RCVS, Mr Chalkley accepted that he had failed to identify some 45% of the animals he had injected on 5 March 2018 and had, in respect of each of the skin thickness measurements for those animals, randomly chosen a figure that he believed would be appropriate based on the breed, age and sex of the animal.
The APHA guidelines state that specific measurements should be made and recorded for each individual animal using callipers. Mr Chalkley said that he could not remember seeing the “pop-up” declaration which appeared when submitting the results to the APHA online and had never read it. He stated that he was not aware that he was making a declaration. However, he accepted that as an Official Veterinarian he was confirming that he had carried out the test properly. While he agreed that he knew that the test contained inaccuracies, he did not accept that he was being dishonest when he submitted the results.
Having considered all the evidence put forward by the RCVS and Mr Chalkley in his own defence, the Committee found that Mr Chalkley had acted dishonestly in deliberately choosing not to take the measurements on 5 March and had instead submitted fabricated alternatives, and so risked undermining public health by failing to carry out his duties as an OV.
The Committee also concluded that Mr Chalkley had been acting dishonestly, as he knew that he was submitting the test results as if they were the authentic outcome of a properly conducted test when in reality, they were no such thing.
The Committee did not accept Mr Chalkley’s evidence that he was unaware of the declaration which accompanied the submission of the test outcome. The Committee therefore found both the first and second charges proved.
In respect of the third charge the Committee found that this was not proven noting that the RCVS had not disproved Mr Chalkley’s explanation regarding his reasons for returning the £20,000 in fees he had received for carrying out TB testing at the farm from the APHA since 2011.
The Committee then considered whether the first two charges, both of which had been found proven, amounted to serious professional misconduct.
Ian Arundale, chairing the Committee and speaking on its behalf, said: “The Committee was prepared to accept that the respondent considered the risk arising from his actions as negligible. Nonetheless, in the Committee’s assessment a real risk existed due to the respondent’s actions and it was precisely the risk which the authorised testing procedure was designed to negate. The simple fact is the respondent could not be sure that each animal he assessed on 8 March 2018 had also been seen by him on 5 March 2018.
“However, the wider point with which the Committee was concerned related to the importance of any member of the profession or public being able to rely absolutely on the integrity of veterinary certification. Those parts of the Code and supporting guidance [concerning certification]… were unequivocal. It was very difficult to conceive of circumstances in which it could ever be justifiable to certify the outcome of a test which had not, in fact, been conducted in a way which was demonstrably valid and reliable. Such conduct was bound to be regarded as disgraceful by members of the profession and the general public.
“Honesty is the bedrock of appropriate certification and the Code and Guidance for the Disciplinary Committee is also unequivocal. Dishonesty in professional practice is always an extremely serious matter and the respondent’s responsibilities in the discharge of his functions as an Official Veterinarian were clear. On this occasion those responsibilities had been compromised.
“For these reasons, the Committee has come to the conclusion that the respondent’s conduct in relation to the facts found proved was disgraceful conduct in a professional respect.”
The Committee then went on to consider the sanction for Mr Chalkley.
The Committee heard oral evidence in mitigation, including from a former colleague who had worked with him in practice since 2006, as well as receiving a large number of written testimonials from various sources that attested to his honesty, integrity, willingness to help others, and charitable work in support of animal welfare.
Mr Chalkley’s counsel, in mitigation, highlighted his long and previously unblemished career, and characterised the conduct as an inexcusable but explicable error of judgement that was entirely isolated and out-of-character. Mr Chalkley’s counsel added that he had not done anything that he thought was seriously wrong, and there was no evidence that any harm had been done and that any risk to public health was not serious.
The Committee accepted that the conduct was isolated and out-of-character and that, furthermore, Mr Chalkley had made early and frank admissions to the APHA and that he had displayed a degree of insight, although the Committee was less confident that he truly understood the seriousness of the potential consequences of his dishonest conduct.
The Committee took into account the aggravating factors, including Mr Chalkley’s breach of trust of his position as an OV, the undermining of the integrity of veterinary certification, dishonesty and the potential public health impacts of his conduct.
Ian Arundale added: “The Committee considered that, having regard to the mitigating features which it had identified, a suspension order would be sufficient to send to the profession and the public a clear signal about the importance to be attached to accurate certification. The Committee considered that in the particular circumstances of this case, a period of three months suspension would be sufficient to achieve this objective.”
The full findings for the case can be found at: www.rcvs.org.uk/disciplinary
Phil Kenward from Farm Vets South West in Bridgewater, Somerset has won a bottle of port from the Veterinary Benevolent Fund for submitting the best practical veterinary tip.
The tip was:
"Do not allow the owner's diagnosis of his problem to worry or influence you before you examine the animal yourself."
The competition was run to celebrate the launch of The Pocket Book of Tips For Practising Vets which can be ordered on-line from the Vetlife website to raise funds for the VBF charity.
Lydia Brown, President of the VBF, said: "This book has been a monumental effort by six mixed practice vets, to both share their experience with the profession and to provide very welcome funds for the veterinary profession's own charity, the VBF. We are currently raising money for the new Vet Helpline e-mail support service which will launch at the end of the year so we are extremely grateful to everybody concerned for all their efforts."
Eskimo, a reindeer at Edinburgh Zoo has received life-saving surgery just in time for Christmas, making him the first reindeer in history to receive keyhole surgery.
Vet Romain Pizzi successfully removed one of Eskimo's testes, which had been lodged in its abdomen since birth, using specialist surgical instruments donated to the zoo by one of Ark Surgical's strategic partners Surgical Innovations.
The zoo was worried that the retained testicle may have been developing into a tumour giving off abnormal hormones, and that this could become life-threatening. Thankfully, zoo surgeons found that the retained testicle, although abnormally sized, had not yet developed a tumour.
It is thought that the abnormal testicle was affecting Eskimo's production and flow of testosterone and, as a result, he was showing submissive behaviour and being bullied by the other male reindeer in the herd. He had also started to show some abnormal and delayed antler growth and development. Removing the testicle will halt any abnormal hormone production so hopefully Eskimo will return to full vigour just in time for Christmas.
Gavin O'Brien, Director at Ark Surgical said: "We were only too happy to help when Romain mentioned the challenging operation faced by Eskimo and in the season of goodwill we approached Surgical Innovations who kindly donated the instruments for this pioneering surgery."
Although laparoscopic surgery is routine in humans, the standard procedure in animals is still open abdominal surgery. Open abdominal surgery is 20 years behind human medical advances and has a number of negative factors on animals such as more post-operative pain, slower recovery and a higher risk of post-operative complications and infections.
Romain, a veterinary surgeon for the Royal Zoological Society of Scotland, based at Edinburgh Zoo, said: "Laparoscopic surgery is still very uncommon in veterinary medicine, even amongst common species such as dogs, cats and horses, so for keyhole surgery to be carried out on a reindeer shows a great advancement in veterinary surgery."
It is estimated that nearly one out of every two households in the UK are pet owners. Veterinary surgeons perform on average 600,000 open abdominal procedures annually but it is believed that less than 1% of vets currently practice laparoscopic surgery.
Romain believes that with the right instrumentation available through innovative companies such as Ark Surgical, UK vets now have more opportunity than ever to introduce laparoscopic techniques as part of their operating procedures.
Romain said: "This procedure was only really possible thanks to a cutting-edge designed retractor which we were able to use in this case. Ironically although a reindeer is a reasonably large animal, due to their unique anatomy and massive four chambered stomach that takes up most of the space in the abdomen, there is a very limited internal operating space. For this reason the operation was much more difficult than in a human, or in a dog, where there is more space to work, despite their smaller size."
"We were especially pleased with how quickly Eskimo recovered after surgery, he was standing and happily eating lichen again within 10 minutes of recovery from anaesthesia. He hardly seemed to notice he had even had surgery, although he was still slightly groggy from the anaesthesia. This would simply not have been possible with traditional open abdominal surgery, as the long wound would have been much more painful and debilitating."
The minimally invasive nature of laparoscopic surgery means there are numerous benefits for animals such as a reduction in post-operative pain, a faster recovery and reduced post-operative care. It also has a decreased risk of infection after surgery and a lower risk of any wound complications.
For veterinary surgeons laparoscopic surgery can offer better visualisation of the operated area, allowing them to be more precise and reach areas that are difficult to see in open surgery such as the liver and pelvic canal.
Romain carries out laparoscopic operations on dogs, cats and exotic pets at his own veterinary practice Inglis Veterinary Centre (Scotland) and has pioneered several new laparoscopic techniques.
He said: "Laparoscopic surgery has so many benefits for the animal, the veterinary surgeons and the zoo, so there is no reason why it should not be more common practice within veterinary surgery. I hope Eskimo's experience helps raise its profile and encourage more veterinary surgeons to look in to it as a standard surgical procedure."
Ark Surgical offers a wide range of laparoscopy instruments and peripherals to vets across the UK and to suit all budgets. The company says it is already working with many of the UK's leading vets and agencies such as the Royal Zoological Society of Scotland, as well as the UK foremost laparoscopic medical device manufacturer Surgical Innovations, to be at the forefront of veterinary laparoscopic surgery
For more information on animal laparoscopic surgery contact Ark Surgical on 01732 862882 or http://www.arksurgical.co.uk/
The responsible use of antibiotics termed critically important is an important strand in the UK policy to fight antibiotic resistance development.
However, NOAH says there is much confusion about which antibiotics should be considered within this group, with different organisations referring to different classes.
Donal Murphy, Head of Technical and Regulatory Affairs at NOAH said: "NOAH believes the classification and use of antibiotics in veterinary medicine should be driven and guided by the regulators, who are independent and make science based decisions and recommendations.
"Of course, all classes of antibiotics, whether critically important or not, should be used responsibly and guided by the principle outlined by the Responsible Use of Medicines in Agriculture Alliance (RUMA) who state they should be used 'as little as possible but as much as necessary'. The use of these important products in this manner can ensure that the availability and efficacy of antibiotics can be maintained to ensure animal health and welfare in the future."
You can download the briefing document here.
The BVA has expressed its concern that almost two-thirds of food companies have no information on their commitment to stunning animals before slaughter – with only 4% having a "universal commitment".
The findings were published in the Business Benchmark on Farm Animal Welfare report (BBFAW, published 27 January) and also show that slaughter without pre-stunning is the only welfare measure showing a decline in the percentage of food companies that have a specific policy on the practice, down from 34% in 2014 to 32% in 2015.
BVA has run a long-standing and high profile campaign to end non-stun slaughter in the UK, with a public petition in 2015 gaining 120,000 signatures. BVA, together with all leading farm animal welfare organisations, believes that all animals should be stunned before slaughter to render them insensible to pain. Scientific evidence supports the use of pre-stunning to safeguard animal welfare. In 2015, two-thirds of BVA members listed the issue as one of their top priorities for government.
BVA President Sean Wensley said: "Vets and the public are united in their concern about animal welfare at slaughter. There are several positive findings on the growing commitment of food companies towards farm animal welfare in the BBFAW report, which we welcome, but the report highlights a disappointing lack of commitment towards animal welfare at the time of slaughter. The European Commission’s study of 13,500 meat consumers across Europe found that 72% wanted information about the stunning of animals at slaughter. Food companies need to sit up and take consumers’ concerns about humane slaughter seriously. People want to be assured that farmed animals receive both a good life and a humane death."
At this year’s event, sessions include ‘Backyard pigs – Notifiable Diseases and Zoonosis’, and a discussion on the role of paraprofessionals in the sector led by Simon Hall, APHA’s Director for EU Exit and Trade.
Drop-in Q&A sessions, workshops offering practical advice and guidance on the revalidation process and a strong focus on the Cymorth TB programme in Wales also feature.
The conference programme includes dedicated lecture streams aimed at large animal, small animal and equine practitioners and, with more than 8,000 OVs due to revalidate their qualifications in March 2019, Improve says lecture content has been tailored to cover areas of key relevance for them.
An exhibition of products and services for OV’s runs alongside the conference.
APHA’s recently appointed Veterinary Director, Dr Andrew Soldan (pictured right), said: "Having recently taken on the role of Veterinary Director for APHA, I am very much looking forward to meeting up with our OV’s and exploring some of the key challenges facing us all, as we seek to control animal disease threats at home and from abroad."
David Babington MRCVS, Business Development Director at Improve International, said: "This conference has established itself as an annual fixture in the OV diary and it remains the only event dedicated to their needs. This year’s packed programme will again highlight the growing importance of OV’s, particularly as we look ahead to the post-Brexit era."
For more information on the Official Veterinarian Conference and Exhibition or to register visit: www.officialvet.com
The MSD Animal Health Research Bursary for Veterinary Surgeons offers three awards, consisting of two ruminant bursaries and one companion animal bursary, of up to £4,000 each.
Each project should be completed within one to two years and the vet practitioner proposals will be judged by university academics to ensure independent assessment.
The companion animal research bursary will be assessed by the University of Nottingham Centre for Evidence-based Veterinary Medicine and the ruminant research bursary applications will be assessed by academic staff from the University of Bristol School of Veterinary Science.
Michelle Townley, veterinary advisor at MSD Animal Health (pictured right) said: "Our Vet Surgeon Research Bursaries have an important role to play in encouraging vet surgeons to continue to develop their research skills. New knowledge and good research skills form the life-blood of the industry so we’re keen to see proposals from both ruminant and companion animal practitioners. Being awarded a bursary has proved to be a career-changing experience for some participants so we’re keen to get as many applications as possible as part of our investment in the veterinary industry."
The deadline for entries is 30th November 2018. For more information, visit www.msdahresearchbursary.co.uk.
The company says Bovela is the only BVD vaccine available proven to provide 12 months’ protection, against both types of BVD, and after only one shot.
Cattle business manager, Robert Bakewell said: "Provided Bovela is used as recommended on the product label, we are happy to guarantee that it will prevent the birth of PI (persistently infected) calves caused by transplacental infection by the BVD virus.
"We are also encouraging farmers to seek advice and input from their vet about BVD control by offering a £50 voucher towards testing for Bovela users. All herd owners need to do is speak to their veterinary surgeon or email bvdzero.uk@boehringer.com."
Merial Animal Health has launched Locatim, an oral antibody supplement to aid calf scour management.
Manufactured from the colostrum of high health status cows that are hyper-immunised against E.coli, rotavirus and coronavirus, Locatim contains a guaranteed concentration of specific antibodies to enterotoxic E.coli F5 (K99).
Merial says that when given alongside the dam’s colostrum, Locatim provides enhanced protection against infection, reducing calf mortality due to neonatal diarrhoea caused by E.coli F5 (K99), and helping to protect calf health during the critical rearing period.
According to the company, a single 60ml oral dose provides direct transfer of these specific antibodies, giving local protection within the digestive tract and systemic protection following absorption through the intestinal mucosa.
For optimal absorption Locatim should be administered during the first four hours of life, but it can be given up to 12 hours after birth.
Locatim can be administered to every calf born during an outbreak of scour; at times of peak calving, when environmental challenge is high; or it can be used to enhance protection in individual calves identified as being at high risk of disease due to factors such as dystocia, weakness or the poor quality of the dam’s colostrum.
For information on purchasing stock contact your local Merial Animal Health territory manager.
The company says Cevaprost can help improve breeding success in reproduction protocols in cattle and has the following indications:
Ceva says these indications are equivalent to those of the leading racemic and single isomer cloprostenols available in the UK.
Cevaprost is available in a 20ml colourless glass vial and in a multi-pack of 10 x 20ml vials. It can be administered in single or repeated 2ml doses (equivalent to 0.5mg of cloprostenol) by intramuscular injection. It has a withdrawal period of one day for meat and no withdrawal period for milk.
Peter Keyte, ruminant business unit manager at Ceva Animal Health, said: “We are delighted to add Cevaprost to our extensive range of reprodAction products to provide vet and farmers with comprehensive cattle reproduction solutions and improve breeding success in reproduction protocols.”
For further information, contact your local Ceva territory manager or email cevauk@ceva.com.
Intervet/Schering-Plough Animal Health is now supplying Cepravin dry cow antibiotic treatment in a new 'flexi-cap' tube which offers two ways of infusing the product into the cows' teats.
According to the company, the new cap is easier to remove and can be quickly flicked off with a fingernail, whilst the shorter, thinner nozzle option may reduce the chances of damaging the teat canal and teat end. Farmers can be assured that administering Cepravin dry cow therapy with a shorter, thinner nozzle still delivers the antibiotic where it needs to be, and at the correct dose.
Jennifer O'Connor, vet adviser at Intervet/Schering-Plough Animal Health said: "The teat canal is a vital barrier to infection. A gentle infusion technique is essential to avoid causing damage, reducing its ability to close properly and form a keratin plug to help keep infection out. We are delighted to be introducing an innovative development for one of the UK's most widely used dry cow tubes."
Norbrook Laboratories has announced the addition of new indications to its Loxicom (meloxicam) products, two regarding its use in cats, and the other in calves.
Loxicom 5mg/ml solution for injection for dogs and cats is now indicated for the management of post-operative pain in cats. An injection given around the time of surgery can be followed up with a course of Loxicom 0.5 mg/ml oral suspension for cats. Alternatively, for cats where no follow-up oral treatment is possible, for example with feral cats, a larger dose of the injectable formulation can be given at the time of surgery.
Norbrook's EU Veterinary Advisor, Rebekah Dudek MRCVS, said: "Norbrook is pleased to be able to now offer vets two on-licence choices in relation to how they want to use their 5mg/ml meloxicam injection in cats. This gives vets the flexibility they need to be able to deal effectively with the wide variety of cases they see every day."
Loxicom 20mg/ml solution for injection for cattle, pigs and horses has now been licenced for the relief of post-operative pain following dehorning in calves.
Norbrook says that the use of a non-steroidal antiinflammatory drug (NSAID) alongside local anaesthetic has clear benefits for animal welfare, and that use at this time is also shown to offer economic benefits to the farmer, with increased food-conversion efficiency compared to untreated calves1.
Rebekah said: "Dehorning in calves has long been known as a painful procedure, with a negative impact on feed intake in the post-operative period. With our latest licence, Loxicom 20mg/ml can now be used for relief of this potentially economically important post-operative pain in calves."
Reference
Maprelin, which contains a new active molecule, Peforelin, is a gonadotropin releasing hormone (GnRH). A single, low volume injection of the ready-to-use solution induces oestrus in sows after weaning, and in sexually mature gilts where oestrus has been synchronised with Regumate Porcine.
According to the company, it works by selectively inducing the release of the animal's own follicle stimulating hormone (FSH), leading to follicle growth - critical to successful reproduction - and the stimulation of oestrus. Conventional GnRHs, because of their mode of action, are used mainly to induce ovulation.
Janssen says Maprelin is the next step in its pig reproduction programme, named Syncoris. Cornerstone of this programme is Regumate for gilt synchronisation.
Trials have shown that with the use of Maprelin (compared with control groups of breeding animals) the number of gilts and sows showing oestrus within six days of treatment increased by about 15 percentage points (Table 1). For first-litter sows the figure was more than 8 percentage points. The duration of oestrus was not affected.
Gilts came on heat two days faster than with Regumate alone, and the weaning to oestrus interval with sows achieved similar statistically significant reductions.
Farrowing rate increased by over 5 per cent for sows, by 6 per cent for first-litter sows and just on 8 per cent for gilts.
Added to those benefits, for each 100 inseminations sows produced an extra 104 piglets, first-litter sows 105 and gilts an even more impressive 158. All gilt groups in the trials, including the control groups, were synchronised with Regumate. With unsynchronised gilts it is not possible to predict the correct time to inject Maprelin.
Phil Macdonald, the company's UK pig and poultry business manager, says the objective of every producer is profitable pigmeat production. "In the UK and other EU states the costs of feed, housing and labour are considerably higher than in other major pig-producing sectors of the world.
"This makes it important for UK producers to optimise management of the reproductive process. Maprelin is a valuable tool that can help with this objective."
The precision injection gun with Maprelin enables accurate delivery of the small amounts required. Gilts require a 2.0 ml dose 48 hours after their last Regumate treatment, first-litter sows a 0.5 ml dose 24 hours after weaning and multi-litter sows 2.0 ml 24 hours after weaning. Injections are intramuscular.
The solution requires no mixing, reducing the possibility for errors. Opened vials have a shelf life of 28 days and unopened vials a shelf life of two years. Sows and gilts need only one injection per parity, and the withdrawal period for meat and offal is zero days.
ECM of France, a specialist in veterinary ultrasound solutions, has launched VIRTUAL SCAN - an ultrasound scanner for pig farmers and veterinarians. ECM says the scanner offers an alternative to screenless A-Mode Doppler devices, cheaper ultrasound devices, which are often poor quality.
VIRTUAL SCAN weighs 450 grams. It is equipped with an internal five-hour battery and a 5MHz sector probe. ECM says the instrument is extremely easy to handle - all the user needs to do is switch it on and the hand-held instrument is instantly ready to perform an ultrasound on sows.
VIRTUAL SCAN is a compact device (11cm x 18.5cm x 4.5cm) and does not require an external cable. According to the company, it can be used in any livestock facility, even inside narrow, hard-to-reach stalls. The screen is positioned in such a way that the image is always visible.
Using ECM's scanner, pregnancy tests can be performed as early as 21 days after insemination, so it is possible to re-inseminate any unfertilised sow without wasting a costly additional cycle. The image is easy to interpret. After use, the VIRTUAL SCAN ultrasound instrument is easy to clean with a damp cloth or water.
ECM, which is headquartered in Angoulême (in south-western France), develops and manufactures specialist veterinary-science devices. The company also provides training in ultrasound techniques, the correct way to move the probe and how to interpret the ultrasound image.
For more information, please contact:
Simon QuarmbyHOLMEFIELD Farm ServiceAgriculture HouseMurton LaneMurtonYorkT019 5UF
tel : (44) 1904 481.490fax : (44) 1904 481.211email : simon@hfsvets.com
Or visit: http://www.agroscan.com/ and http://www.ecmscan.com/
BCF, Instrumentation Concept and VetSonic have collected 'VetSurgeon.org Best Stand Awards'; the first two at BEVA Congress and the latter at BCVA Congress.
Judging for the BEVA Congress awards was undertaken by members of BEVA Council. BCF picked up the Best Large Stand Award which was presented by outgoing President, Andrew Harrison.
Pictured left to right: BEVA President, Andrew Harrison, Gavin Mitchell and Carole Irvine of BCF, and John Alborough representing VetSurgeon.org.
Instrumentation Concept picked up the Best Shell Scheme Award
Pictured left to right: Outgoing BEVA President, Andrew Harrison; Tahir Afzac of Instrumentation Concept; John Alborough representing VetSurgeon.org, and Sheraz Ishaque of Instrumentation Concepts
At BCVA Congress, Vetsonic won the Best Stand Award.
Pictured left to right: Clare Walsh, Vetsonic Director; John Alborough, All Round Good Egg representing VetSurgeon.org; Gareth Hateley, then President BCVA and Sarah Vermont, Marketing Manager Vetsonic.
An impurity was detected during stability monitoring. The impurity was isolated and the best estimate of identity indicated that the impurity is carprofen related.
The problem affects a limited number of batches and is identifiable through quality control testing. The concentration of the process impurity does not increase over time.
This recall is for the following batches only:
Norbrook is contacting wholesale dealers and veterinary surgeons to examine inventory and quarantine products subject to this recall.
For further information regarding the recall, contact Gary Mckee on 0044 2830 264435 or by email: gary.mckee@norbrook.co.uk
Dechra Veterinary Products has launched Cyclo Spray, an antibiotic spray for veterinary professionals treating hard to reach sites when handling cattle, sheep and pigs.
Dechra says the new product has been developed for use at any angle, even upside down.
Cyclo Spray (chlortetracycline hydrochloride 2.45%) is indicated for the treatment of superficial claw and hoof infections and the prevention of infections of superficial traumatic or surgical wounds.
Dechra Veterinary Products Brand Manager Emma Jennings said: "Vets dealing with livestock can often find that they are twisting themselves into awkward positions to get to hard to reach sites with traditional spray can treatments. Not only are they having to find the right angle to ensure the can works, but also potentially the treatment can drip or take time to dry.
"We've introduced Cyclo Spray to our portfolio to help combat some of those difficulties - it is a new 360 degree spray can allowing users to mark the site of application with confidence from whatever angle. It is non-drip, fast-drying with excellent adhesive characteristics and contains a non-toxic colouring agent."
Cyclo Spray is available in 211ml and 422ml can sizes. No withdrawal days are required for meat and milk.
To promote the launch of the new product, Dechra has also launched a competition giving entrants the chance to win a two day trip to London for two people to ride the London Eye and experience the capital from a 360 degree vantage point.
To enter the competition, with the prize including return rail travel, and dinner, bed and breakfast in a 4* hotel, visit www.dechra.co.uk to download an entry form.
Intervet/Schering-Plough Animal Health has announced the launch of Nuflor Minidose - a 50% more concentrated, but less viscous solution of its proven Nuflor antibiotic.
Nuflor Minidose is licensed for the treatment and prevention of bacterial BRD. Intervet/Schering-Plough Animal Health livestock veterinary adviser Rosemary Booth MRCVS said: "It delivers all the rapid efficacy entrusted in Nuflor, but at a lower volume. Whereas a 20ml dose of Nuflor will treat a 150kg animal, the same volume of Nuflor Minidose will cover a 225kg beast. Compared with Nuflor, the new Minidose formulation is easier to administer delivering a less viscous florfenicol solution, with a 62% improvement in viscosity at 15°C and 59% at 5°C."
Rosemary added that Nuflor Minidose is effective against the main bacterial causes of pneumonia: P. multocida, M. haemolytica and H. somni. "Florfenicol is the only antibiotic offering 100% sensitivity to these three key BRD causes in recent trials and its kill effect also ensures that within 24 hours bacteria levels are low enough to prevent any re-growth."
She also pointed out that the new, more concentrated florfenicol solution presents vets with an improved batch treatment option for controlling BRD considering Nuflor is recognised as an effective metaphylactic
"Batch treatment prevents BRD from spreading. Trials with Nuflor have demonstrated the benefit of metaphylactic batch treatment of sick calves in a pen once at least 20% of the animals exhibit disease symptoms. Nuflor was significantly more efficacious than a control in preventing the spread of BRD in healthy calves exposed to infected animals," she explains.
"The bacteria responsible for BRD are found in the respiratory tract of healthy cattle and stress or a greater pathogen load - such as exposure to sick calves - can easily trigger disease. BRD bacterial numbers can double every 30 minutes and in 24 hours, one bacterium can multiply to billions. Batch treatment kills the bacteria before they multiply, release toxins and cause permanent lung damage."
New Nuflor Minidose is licensed for injection subcutaneously for the prevention of BRD at a dose rate of 4ml/45kg and has a 64-day meat withdrawal period.
The study, published in Nature Scientific Reports, investigated the effect of culling in the first three licensed badger cull areas – Gloucestershire, Somerset and Dorset – using data from 2013 to 2017.
Gloucestershire and Somerset saw reductions in bTB incidence rates in cull areas relative to comparison areas of 66 per cent and 37 per cent respectively after four years. In Dorset, there was no change in incidence rates in cull areas relative to comparison areas after two years, but incidence dropped by 55 per cent in the same period in the 2km buffer zone around the edge of the cull area. Matched comparison areas were similar but not identical.
James Russell, BVA Junior Vice President said: "These findings are encouraging and offer further evidence that badger culling can result in significant reductions in the number of new cases of TB in cattle. However, they come with the caveat that the data only relates to the first three cull areas, and the variability within these alone makes it too early to draw firm conclusions that culling will reduce incidence significantly in all 40 areas where it is now taking place.
"BVA’s expert working group is currently considering all aspects of disease control looking at cattle testing, removal of reactors, compensation and control in other farmed animals as well as the culling and vaccination of badgers. The group will consider this additional evidence as we develop our new policy on bTB.
"We continue to support a comprehensive and evidence-based approach to tackling bTB, including the use of badger culling where there is a demonstrated need and where it is done safely, humanely and effectively as part of a comprehensive strategy.
"The best way of halting the spread of this devastating disease is enhancing our understanding of bTB and applying that evidence to the eradication process.”
The allied professionals that the BVA says should be led by veterinary surgeons include: Registered Veterinary Nurses (RVNs), Official Auxiliaries/ Meat Hygiene Inspectors, embryo transfer technicians, equine dental technicians, foot trimmers, farriers, hydrotherapists, animal behaviourists and veterinary physiotherapists.
To clarify where the responsibility for a patient sits and how it is shared between veterinary surgeons and allied professionals, the new policy statement also calls for:
The regulation of allied professionals to include mandatory veterinary diagnosis and oversight and appropriate access to veterinary records as pre-requisites before treatment;
Clarity on the delegation of duties for RVNs under Schedule 3 of the Veterinary Surgeons Act and protection of the ‘veterinary nurse’ title in legislation;
Consultation with the veterinary profession on any regulatory changes that may arise as a result of technological or other innovation.
British Veterinary Association President Simon Doherty (pictured right) said: "Against an evolving landscape, it’s essential that the veterinary profession keeps pace with change and addresses the challenges and opportunities it presents.
"Vets across sectors have always worked closely with allied professionals. The hub and spoke model acknowledges and clarifies this working relationship with clear lines of accountability and responsibility for the animals under our care. It also emphasises that vets’ right to diagnose, prescribe, and undertake surgical procedures and medical treatments must not be undermined.
"An effective and efficient vet-led team can help deliver better animal health and welfare, improved client care, and more effective use of skills within the veterinary professions. Given the ongoing workforce shortages, a strengthened veterinary workforce also has the potential to ease recruitment and retention concerns for both vets and RVNs and offer improved wellbeing.
"BVA will continue working with professional bodies and organisations to formalise the hub and spoke model, promote the value of regulation, and drive up professional standards."
The award, funded by the Economic and Social Research Council (ESRC) working in partnership with the Department of Health and the Arts and Humanities Research Council (AHRC), is part of the cross-council 'Tackling antimicrobial resistance: behaviour within and beyond the healthcare setting’ call, part of the antimicrobial resistance cross-council initiative supported by the seven research councils in partnership with other UK funders including the Medical Research Council (MRC).
The research team will be led by social scientists at the University of Exeter and includes two veterinary surgeons from the University of Bristol’s School of Veterinary Sciences, together with colleagues at the Innogen Institute of the University of Edinburgh, the British Veterinary Association and leading farm animal veterinary surgeons across the UK.
The researchers say that better, smarter, more rapid and more accessible diagnoses - driving shifts in behaviour associated with diagnostic decision making - represent a critical step to delivering more effective uses of antibiotics in animal health. But improvements in diagnostic development and their relationship to prescription and treatment requires social, governance and technical innovations.
Professor Henry Buller, project lead from the University of Exeter’s School of Geography, said: "This is an exciting opportunity to provide a current assessment of diagnostic and treatment decision practices in the livestock sectors of the UK. Novel and innovative diagnostic tools are currently in development, and our research will generate better understanding of their development as well as the marketing and regulation of these new technologies."
Dr Kristen Reyher, Senior Lecturer in Farm Animal Science, who is the lead on the project at the University of Bristol’s School of Veterinary Sciences, added: "Our research team – the AMR Force – has a track record of working closely with farmers, veterinarians, retailers and government bodies to encourage responsible use of antibiotics. We are excited to have this amazing opportunity to collaboratively generate, evaluate and analyse behaviours and strategies around animal disease diagnosis and to show how innovation in the development of diagnostic tools along with diagnostic regulation and governance can lead to more sensible use of antibiotics across farming systems.
"Working with our partners, we will identify pathways and possibilities for improved diagnostic practice and will trial new diagnostic tools on a series of farms. We are very excited to take our ideas beyond the UK as well, and will conduct pilot and capacity-building research in Tanzania and also partner with a project working in Bangladesh that is co-funded by ESRC and the Centre for Environment Fisheries and Aquaculture Science."
Professor Buller added: "Employment of new diagnostics doesn’t occur in a vacuum. Our team will evaluate the implications these innovations will have for the organisation, cost-effectiveness and efficiency of veterinary practice, as well as for veterinary training. We will identify the changes in behaviour, practice and knowledge necessary to accompany the more widespread adoption of practices that are deemed effective and will assess the regulatory and governance support necessary to encourage use of beneficial practices."
The interdisciplinary team will work alongside diagnostic tool developers and regulators, veterinary practices and professional bodies, farmers and treatment decision makers, veterinary laboratories, the food industry and government regulatory authorities to develop durable and innovative strategies for facilitating and advancing smarter approaches to the use of antibiotics in agriculture.
The work will cover the major livestock species, and will involve seeking opinions from veterinary surgeons across the country, through collaboration with the BVA.
David Barrett, Professor of Bovine Medicine, Production and Reproduction at the University of Bristol’s School of Veterinary Sciences, said: "This is a fantastic opportunity to assess the adaptability and responsiveness of the different animal production sectors - poultry, pigs and cattle - along with a variety of veterinary structures to the trialled innovations in diagnosis and diagnostics, and will determine the likely benefits of these innovations for prescription practice, for animal health and for sustainable livestock production."
Photo: University of Bristol
MSD Animal Health has obtained regulatory approval in 21 European countries, including the UK, for Cobactan LA 7.5% (cefquinome) - a new-generation, injectable antimicrobial for the treatment of swine respiratory disease (SRD).
Raul Berro DVM, global marketing director swine at MSD Animal Health said: "Cobactan LA 7.5% is a long-acting version of our highly effective Cobactan 2.5%. Its longer duration of action means greater compliance for swine producers with fewer injections and less stress to the animals, without sacrificing performance."
According to the company, the long-acting antibiotic formulation is effective against three major SRD pathogens in growing and finishing pigs - Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida. Considered the most important threat to the swine industry worldwide, SRD causes increased mortality, decreased weight gain and increased feed consumption.
Cobactan LA 7.5% requires two intramuscular injections 48 hours apart, compared to Cobactan 2.5%, which requires three daily injections. The recommended dose rate is 1 mL (3 mg cefquinome) per 25 kg bodyweight. The product isavailable in 50-ml, 100-ml and 250-ml glass vials.
Raul aded: "COBACTAN LA 7.5% also has a short withdrawal period of seven days. This makes the injectable product also safe to use throughout the finishing period for the treatment of SRD."
MSD adds that the use of COBACTAN LA 7.5% should be according to established responsible use guidelines and strictly according to the label instructions where specific restrictions apply to this class of antibiotics.
For more information, contact your local MSD Animal Health representative or go to www.msd-animal-health.com.